AbbVie Enters the Battle of the Biosimilars
January 15, 2016
Khadijah M. Silver
Institutional Investor
Axinn partner Chad Landmon was quoted in the Institutional Investor's article, "AbbVie Enters the Battle of the Biosimilars."
Axinn partner Chad Landmon was quoted in the Institutional Investor's article, "AbbVie Enters the Battle of the Biosimilars."